|Systematic (IUPAC) name|
|Mol. mass||228.118 g/mol|
DOV 102,677 is a psychoactive drug being developed by Merck as an antidepressant and is currently in clinical trials. It is a so-called triple (re)uptake inhibitor (TUI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the (-)-enantiomer of DOV 216,303, and its (+)-enantiomer is DOV-21,947 (amitifadine).
"DOV 102,677 (20 mg/kg IP) increased extracellular levels of DA and 5-HT in the prefrontal cortex to 320 and 280% above baseline 100 min after administration. DA levels were stably increased for the duration (240 min) of the study, but serotonin levels declined to baseline by 200 min after administration. NE levels increased linearly to a maximum of 348% at 240 min post-dosing."
- N.B. Milnacipran also uses epichlorohydrin and phenylacetonitrile in most of the syntheses for this compound.
- Popik, P.; Krawczyk, M.; Golembiowska, K.; Nowak, G.; Janowsky, A.; Skolnick, P.; Lippa, A.; Basile, A. (2006). "Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677". Cellular and molecular neurobiology 26 (4–6): 857–873.
- Mcmillen, B.; Shank, J.; Jordan, K.; Williams, H.; Basile, A. (2007). "Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat". Alcoholism, clinical and experimental research 31 (11): 1866–1871.